MedTrace Logo

Biomarkers in DNA Samples From Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine-Based Therapy

NCT01145469 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 225

Last updated 2017-05-17

No results posted yet for this study

Summary

RATIONALE: Studying samples of DNA in the laboratory from patients who received fludarabine-based treatment may help doctors learn more about the effects of fludarabine on cells. It may also help doctors understand how well patients respond to treatment.

PURPOSE: This research study is studying DNA samples from patients with chronic lymphocytic leukemia previously treated with fludarabine-based therapy.

Conditions

Interventions

GENETIC

DNA analysis

GENETIC

gene expression analysis

GENETIC

polymorphism analysis

OTHER

laboratory biomarker analysis

OTHER

medical chart review

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eastern Cooperative Oncology Group

    lead NETWORK

Principal Investigators

  • Tait D. Shanafelt, MD · Mayo Clinic

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-01
Primary Completion
2010-08-01
Completion
2010-08-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01145469 on ClinicalTrials.gov